AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT00505232 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Y-90 Ibritumomab tiuxetan
Description: Study Design~The present study will be split into two cohorts:~1. Patients younger than 60 years who will receive 8 chemotherapy cycles~2. Patients older than 60 years who will receive 6 chemotherapy cycles~The induction schema summarises as follows :~Anti-CD20/Hyper -CVAD chemotherapy will be alternated with anti-CD20 +MTX/Ara-C chemotherapy twice. Afterward, response will be evaluated, followed by, either, four cycles further patients younger than 60 years who will obtain a CR or PR, or 2 cycles patients older than 60 y. (see figure 1 and flow chart).~Consolidation treatment will consist in a single dose of Y90-Ibritumomab -Tiuxetan (Zevalin) \[0.4 mCi/Kg b.w or 0.3 mCi/kg if platelets \< 100,000/µl\] will be administered 8 to 12 weeks after last chemotherapy.
Study NCT03629041 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Microneedle Patch
Description: At the first visit participants will have either the buccal or palatal treated. At the second visit the other area will be treated.
Study NCT03629041 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Patch with no microneedles
Description: At the first visit participants will have either the buccal or palatal treated. At the second visit the other area will be treated.
Study NCT02230878 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JNJ-42847922 5 mg
Description: Participants will receive 5 mg of JNJ-42847922, from Day 1 up to Day 10.
Study NCT02230878 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JNJ-42847922 10 mg
Description: Participants will receive 10 mg of JNJ-42847922, from Day 1 up to Day 10.
Study NCT02230878 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JNJ-42847922 20 mg
Description: Participants will receive 20 mg of JNJ-42847922, from Day 1 up to Day 10.
Study NCT02230878 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JNJ-42847922 40 mg
Description: Participants will receive 40 mg of JNJ-42847922, from Day 1 up to Day 10 .
Study NCT02230878 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Participants will receive matching placebo from Day 1 up to Day 10.
Study NCT02815293 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AGN-195263
Description: 1 drop of AGN-195263 will be instilled in each eye twice daily.
Study NCT02815293 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Vehicle
Description: 1 drop of AGN-195263 vehicle (placebo) will be instilled in each eye twice daily.
Study NCT03508765 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Structural Image
Description: Patients will undergo structural and functional (rsfMRI) brain MRIs (total time= \~15 minutes) at enrollment (prior to HD-Chemo/ASCT) and approximately 3-4 months after ASCT.
Study NCT03508765 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Functional Image
Description: Patients will undergo structural and functional (rsfMRI) brain MRIs (total time= \~15 minutes) at enrollment (prior to HD-Chemo/ASCT) and approximately 3-4 months after ASCT.
Study NCT03508765 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Digit Span subtest
Description: Evaluates auditory attention and working memory
Study NCT03508765 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Brief Test of Attention
Description: Assesses selective auditory attention
Study NCT03508765 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Trail Making Test (Parts A & B)
Description: Assesses visual scanning, graphomotor speed, and setshifting
Study NCT03508765 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Auditory Consonant Trigrams Test
Description: Assesses attention and susceptibility to interference
Study NCT03508765 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Controlled Oral Word Association Test
Description: A timed test of verbal fluency.
Study NCT03508765 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Hopkins Verbal Learning Test-Revised
Description: The HVLT-R is a test of verbal learning and recall.
Study NCT03508765 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: The Center for Epidemiological Study-Depression
Description: assesses perceived depression
Study NCT03508765 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: The Functional Assessment of Chronic Illness Therapy-Fatigue Subscale, Version 4
Description: A 13-item questionnaire designed to assess symptoms and concerns specific to the QOL of patients with fatigue
Study NCT03508765 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Blood draw
Description: Blood samples will be collected at each time point (pre-ASCT; 3-4 months and post-ASCT) to assess serum levels of inflammatory cytokines.
Study NCT00511342 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NOMAC-E2
Description: Nomegestrol Acetate and Estradiol Tablets, 2.5 mg NOMAC and 1.5 mg E2 taken once daily from Day 1 of menstrual period up to and including Day 28 for 26 consecutive 28-day menstrual cycles (2 years).
Study NCT00511342 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: LNG-EE
Description: Levonorgestrel and Ethinyl Estradiol Tablets, 0.150 mg Levonorgestrel and 0.030 mg Ethinyl Estradiol taken once daily from Day 1 of menstrual period up to and including Day 28 for 26 consecutive 28-day menstrual cycles (2 years).
Study NCT02370017 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: ANKL(Ex vivo-expanded NK cell enriched lymphocytes)
Description: add ANKL in 3rd and 4th course in case of stable response after two initial courses
Study NCT03201952 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ursodeoxycholic Acid
Description: Ileostomy administration of 300mg UDCA once
Study NCT03201952 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebos
Description: Ileostomy administration of 5cc saline placebo once
Study NCT00897325 — intervention group
Intervention type: OTHER
Intervention: Cytology Specimen Collection Procedure
Description: Correlative studies
Study NCT00897325 — intervention group
Intervention type: OTHER
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies
Study NCT03585322 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: APG-1387 for Injection
Description: Multiple dose cohorts, 30 minute IV infusion, once weekly for 4 weeks .
Study NCT02432040 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atorvastatin
Description: Atorvastatin is a hydroxymethylglutaryl-coenzyme A (HMG-CoA) reductase inhibitor used to treat dyslipidemia
Study NCT02432040 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo tablets, made to look like the interventional drug
Study NCT01645423 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Atorvastatin Calcium Tablets, 80 mg
Description: Atorvastatin Calcium Tablets, 80 of Dr. Reddy's Laboratories Limited
Study NCT02363452 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Reverse transcriptase inhibitors: Zidovudine, Lamivudine, Abacavir
Description: Oral Solution (syrup) or Tablets
Study NCT02541591 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Neuroprotective goal directed hemodynamic optimization
Study NCT02541591 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: MAP > 65mmHg
Description: MAP > 65mmHg
Study NCT03323957 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: nutritional screening tool
Description: screening of disease associated malnutrition in sick infants
Study NCT03232788 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Bone regeneration
Description: Autogenous bone will be placed over periodontal defect after root treatment with scaling and root planing.
Study NCT03232788 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Bone regeneration
Description: Autogenous bone will be placed over periodontal defect after root treatment with scaling and root planing.
Study NCT03232788 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Collagen membrane
Description: A collagen membrane will be used to cover the autogenous bone.
Study NCT03232788 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Scaffold
Description: A hydroxyapatite and polycaprolactone scaffolds will be used to cover the autogenous bone.
Study NCT03399448 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: NY-ESO-1 redirected autologous T cells with CRISPR edited endogenous TCR and PD-1
Description: Autologous T cells transduced with a lentiviral vector to express NY-ESO-1 and electroporated with CRISPR guide RNA to disrupt expression of endogenous TCRα, TCRβ and PD-1 (NYCE T Cells).
Study NCT03804398 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: PEEP level of 5 cmH2O
Description: In the control group at PEEP level of 5 cmH2O was established and maintained during the study period
Study NCT04030494 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: BP measurement
Description: sequential BP measurement with Withings WPM04 and sphygmomanometer with dual observer auscultation
Study NCT04030494 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: AF detection
Description: single lead ECG with Withings WPM04 and 12 lead ECG
Study NCT04030494 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: VHD detection
Description: phonocardiogram with digital stethoscope of Withings WPM04 and Doppler echocardiography
Study NCT02610816 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: 1 Food Elimination Diet
Description: Participants eliminate milk from the diet for 12 weeks
Study NCT02610816 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: 4 Food Elimination Diet
Description: Participants eliminate milk, egg, wheat, soy from the diet for 12 weeks
Study NCT02610816 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: 4 Food Elimination Diet (post 1FED failure)
Description: Participants that fail to respond to 1FED in phase 1 eliminate milk, egg, wheat, soy from the diet for 12 weeks in Phase 2
Study NCT02610816 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Fluticasone Propionate, 800 mcg twice daily (post 4FED failure)
Description: Participants that fail to respond to 4FED in phase 1 administer swallowed glucocorticosteroids (Flovent HFA) 800 mcg twice daily for 12 weeks in Phase 2
Study NCT02032251 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: oral administration of ginger
Description: Oral administration of ginger in patients with infertility.
Study NCT02032251 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT00789269 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: rhubarb
Description: 14 days of rhubarb
Study NCT00789269 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: 14 days of placebo
Study NCT03026335 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Positive Action
Description: Based upon a Cognitive Behavioral Therapy model, intervened schools were engaged in providing curriculum, school infrastructure elements, and parent/community involvement activities around a single model aimed to provide positive support for behaviors. Six areas were identified: self-concept, body/mind, responsible self-management, treating others they way you want to be treated, telling yourself the truth, and continual improvement of self.
Study NCT03026335 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Control
Description: Business as usual with students in non-itervened schools
Study NCT04448093 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: dental treatment
Description: Dental treatment of adequacy of oral environment and assessment of quality of life and self-esteem through questionnaires comparing a group that received treatment with another that did not.
Study NCT03268694 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Working Memory Task
Description: Sternberg Task Items, which can be visually presented alphabets, shapes or numbers or sound tones presented through speakers, will be presented to the participant. The participant will need to maintain the presented items in their memory and indicate, when a single probe item is presented, whether the probe item was present in the immediately preceding list by pressing a key on the keyboard.~N-Back Task Items are presented continuously sequentially and participants are instructed to indicate whether items are repeated n items before by pressing a key on the keyboard. The task is divided into blocks of 0,1,2,3 -back trials based on the 'n'. For example in the 2 - back task, the participant has to indicate if the item presented 2 items before matches the current item. Similar to the previous task, the items can be presented visually or auditorily.
Study NCT03268694 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Reward Learning Task
Description: Two abstract visual stimuli are presented on the screen and participant is asked to choose one. Unknown to the participant, each stimulus is associated with distinct probabilities of virtual reward such that one stimulus is associated with net gain while the other is associated with net loss. The participant's goal is to maximize the reward. Once the participant identifies the stimulus associated with net gain, the reward probabilities are reversed. This process is repeated 5 times.
Study NCT00734201 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: V24343
Description: Oral, 1mg, 2 mg, 5 mg or 25 mg, or placebo, once daily for 28 days
Study NCT03268694 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Facial Emotion Recognition Task
Description: On a given trial, participants will be presented with images of two faces side-by-side. The faces will either match in terms of emotion category (e.g., 2 anger faces) or not (e.g., an anger face and a fear face). Faces presented together will always be of the same gender but different identities. Participants will be asked to determine whether the two faces presented depict the same emotion category.
Study NCT04380974 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: OCTA plus OCT guided 3+PRN regimen
Description: For the OCTA plus OCT guided 3+PRN regimen, we recorded patients' data after retreatment by 3 monthly intravitreal injections of anti-VEGF drug. Subsequent reinjections were given as needed according to the changes in patients' visual acuity, activity of PCV lesions shown by OCTA and/or the exudation shown by OCT. Four weeks after the third and last injection, all patients in this group underwent an examination, including ETDRS visual acuity, fundus photography, OCTA and OCT.~In case of BVN increased or polypoidal lesion progressed on OCTA scans, persistent subfoveal or perifoveal fluid, macular intraretinal edema on OCT scans, or visual loss of >5 letters, or the occurrence of a new hemorrhage, patients were retreated. The persistence of hemorrhage without evidence of fluid was not considered a criterion for retreatment. In the absence of retreatment criteria, no further injections were given and another examination was proposed usually 4 weeks later.
Study NCT04380974 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: OCT guided 3+PRN regimen
Description: For the OCT guided 3+PRN group, we recorded patients'data after retreatment by 3 monthly intravitreal injections of Anti-VEGF drugs. Subsequent reinjections were given as needed according to the changes in patients'visual acuity and/or the exudation shown by OCT. Four weeks after the third and last injection, all patients in this group underwent an examination, including ETDRS visual acuity, fundus photography, and OCT.~In case of persistent subfoveal or perifoveal fluid, macular intraretinal edema, visual loss of >5 letters, or the occurrence of a new hemorrhage, patients were retreated. The persistence of hemorrhage without evidence of fluid was not considered a criterion for retreatment. In the absence of retreatment criteria, no further injections were given and another examination was proposed usually 4 weeks later.
Study NCT04380974 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Anti-VEGF drug
Description: Conbercept or other anti-VEGF drugs
Study NCT04380974 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Anti-VEGF drug
Description: Conbercept or other anti-VEGF drugs
Study NCT01611350 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: RCT 1- Testing the Effectiveness of Marketing Messages in Increasing Willingness to Pay
Description: We are testing whether any marketing messages effect participants willingness to pay for the fuel efficient cookstoves. All marketing messages are true.
Study NCT01252719 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Single-Dose IV Oritavancin Diphosphate
Description: Oritavancin was administered as a single IV dose.
Study NCT01611350 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: RCT 3-Measure the Effects of Fuel Efficient Cookstoves on Health, Fuel Use and Time Spent Collecting Fuel
Description: Of those who accept the Novel Sales Offer, half the group will be randomly selected to start their free trial early while the other half will receive their free trial late. Those who receive their free trial late will serve as a control group for fuel consumption and Particulate Matter exposure in kitchens.
Study NCT01611350 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: RCT 2- Testing the Effectiveness of the Novel Sales Offer and its ability to Increase Uptake of Purchasing Energy Efficient Cookstoves
Description: We are testing whether households who receive the Novel Sales Offer have higher uptake than those households who receive the Traditional Sales Offer.
Study NCT00503880 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: filgrastim
Description: subcutaneously one day prior to treatment
Study NCT00503880 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: clofarabine
Description: single IV dose over 1 hour daily for 5 days
Study NCT00503880 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cytarabine
Description: subcutaneously daily for 5 days 2-4 hours following the end of the Clofarabine infusion
Study NCT00503880 — intervention group
Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: microarray analysis
Description: Both standard cytogenetic testing and FISH (fluorescent in situ hybridization) are adequate to assess responses.
Study NCT00503880 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: biopsy
Description: bone marrow biopsy
Study NCT01252719 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: IV Vancomycin
Description: Intravenous vancomycin was administered for a minimum of 7 days and up to a maximum of 10 days.
Study NCT01252719 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Intravenous placebo was administered thereafter, for a minimum of 7 days and up to a maximum of 10 days (oritavancin and placebo).
Study NCT02311920 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Ipilimumab
Description: Given IV
Study NCT02311920 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies
Study NCT02311920 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: Given IV
Study NCT02311920 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Temozolomide
Description: Given PO
Study NCT03666481 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Motivational Physical Activity Intervention (MPAI)
Description: MPAI was carried out during 6 consecutive months. The sessions were directed by sport sciences professionals, who were trained in the application of motivational strategies based on self-determination theory.~The frequency of training, as well as the duration of the sessions, was increasing throughout the 6 months. The contents of the sessions could be directed in two ways: sessions with activities to develop cardiorespiratory fitness and muscular strength, and playful sessions to enhance psychosocial aspects. Nevertheless, motivational strategies were implemented in both types of sessions.
Study NCT03866018 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Adapted physical activity
Description: 12 sessions of one hour of adapted physical activity.
Study NCT02359201 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: V0018
Description: Oromucosal - Single dose
Study NCT02359201 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Oromucosal - Single dose
Study NCT02736682 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Single dose antibiotic
Description: Single dose arm receive 2g of IV Ceftriaxone and 500 mgs ofIntra venous Metronidazole given to the mothers 30-60 minutes pre operative.
Study NCT02736682 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Multiple dose antibiotic
Description: Multiple dose arm receive 1 g of IV Cetriaxone plus 500 mgs during surgery and there after IV ceftriaxone once a day for 3 days and IV Metronidazole 500mgs during surgery and there after every 8 hours for 3 days.
Study NCT02904668 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: self-managmeent program
Description: One session was a session supervised by a physical therapist in the Faculty of Health Sciences. The program contents were educative information about chronic neck pain and healthy lifestyle habits (application of local heat/cold, and sleeping face down, using correct sitting posture, alternating body position, and using correct lifting technique (...), which were complemented by a problem-based session.